EXCEED THE SPACE PROVIDED. ttypertenslon is a common manifestation of renal disease and greatly contributes to its progression as well as to cardiovascular morbidity. Clearly, hypertension is an important etiology in the pathogenesis of renal failure. In the United States, hypertension is the primary cause of end-stage renal disease in approximately 29% of dialysis patients. In conjunction with other diseases such as diabetes and chronic glomerulonephritides, hypertension, when uncontrolled, hastens the progression of renal disease. Cardiovascular disease is the leading cause of death in patients receiving maintenance hemodialysis and hypertension is considered the most important factor responsible for cardiovascular events in these patients. Adequate BP control may reduce the progression of renal disease and cardiovascular morbidity in these patients, but often this is difficult to achieve with currently available drugs. The old paradigm is that hypertension in renal disease is the result of activation of the renin-angiotensin system and/or volume expansion. Our studies strongly support the notion that a renal injury may result in activation of renal afferent pathways that integrate with the central nervous system, and lead to stimulation of efferent SNS activity and hypertension. Locally produced angiotensin II in the brain in response to these afferent stimuli seems to be responsible for SNS activation through inhibition of nitric oxide. Our hypothesis is that angiotensin-II activation of ROS may reduce NO availability in key brain region and result in increased SNS activity in a model of neurogenic hypertension caused by renal injury developed in our laboratory. To test this hypothesis we will pursue 3 specific Aims: 1. Test the hypothesis that locally produced Ang II mediates the activation of central SNS activity caused by phenol-renal injury. To this end, we will measure Ang II concentration in the dialysate collected from the PH using the microdialysis technique, and the expression of renin mRNA in the posterior hypothalamus. 2. Test the hypothesis that radical oxygen species (ROS) activated by Angiotensin II down-regulate nitric oxide production in the brain resulting in increased SNS activity. To this end, we will measure the concentration of reactive oxygen species (ROS) in the hypothalamus or rats with the phenol-renal injury or rats infused with Ang II in the lateral ventricle. In addition, we will evaluate the effects of anti-oxidants, or scavengers of ROS, and Ang II AT1 receptor antagonists on BP, sympathetic activation and ROS concentrations in the hypothalamic region. 3. Test the hypothesis that increased ROS production may result in NO inhibition and SNS activation in other forms of experimental hypertension, such as the DOCA-sait model, and the renovascular hypertension model. If our hypothesis were to be correct, administration of inhibitors of the renin-angiotensin system particularly if combined with antioxidants should result in better control of BP in these models. PERFORMANCESITE( ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL071792-03
Application #
6832785
Study Section
Cardiovascular and Renal Study Section (CVB)
Program Officer
Velletri, Paul A
Project Start
2003-01-24
Project End
2006-12-31
Budget Start
2005-01-01
Budget End
2005-12-31
Support Year
3
Fiscal Year
2005
Total Cost
$371,345
Indirect Cost
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Wolak, Talya; Kim, HyunJu; Ren, Yuelan et al. (2009) Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 76:32-43
Bai, Yongli; Jabbari, Bahman; Ye, Shaohua et al. (2009) Regional expression of NAD(P)H oxidase and superoxide dismutase in the brain of rats with neurogenic hypertension. Am J Nephrol 29:483-92
Moradi, Hamid; Pahl, Madeleine V; Elahimehr, Reza et al. (2009) Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 153:77-85
Vaziri, Nosratola D (2008) Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol 295:H454-65
Park, Jeanie; Campese, Vito M; Middlekauff, Holly R (2008) Exercise pressor reflex in humans with end-stage renal disease. Am J Physiol Regul Integr Comp Physiol 295:R1188-94
Park, Jeanie; Campese, Vito M; Nobakht, Niloofar et al. (2008) Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol 105:1873-6
Kim, Choong H; Vaziri, Nosratola D; Rodriguez-Iturbe, Bernardo (2007) Integrin expression and H2O2 production in circulating and splenic leukocytes of obese rats. Obesity (Silver Spring) 15:2209-16
Bai, Y; Ye, S; Mortazavi, R et al. (2007) Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney. Am J Physiol Renal Physiol 292:F974-80
Rodriguez-Iturbe, Bernardo; Sepassi, Lili; Quiroz, Yasmir et al. (2007) Association of mitochondrial SOD deficiency with salt-sensitive hypertension and accelerated renal senescence. J Appl Physiol 102:255-60
Campese, Vito M; Ye, Shaohua; Zhong, Huiqin et al. (2004) Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol 287:H695-703